Published in Neuropsychopharmacology on May 24, 2013
Whoonga: potential recreational use of HIV antiretroviral medication in South Africa. AIDS Behav (2014) 1.15
Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV. J Transl Med (2016) 0.81
Substance use in older HIV-infected patients. Curr Opin HIV AIDS (2014) 0.79
Antiretroviral drug use in a cross-sectional population survey in Africa: NIMH Project Accept (HPTN 043). J Acquir Immune Defic Syndr (2016) 0.78
Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race. Pharmacogenet Genomics (2016) 0.76
Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz. Pharmacol Res (2016) 0.75
The dual modulatory effects of efavirenz on GABAA receptors are mediated via two distinct sites. Neuropharmacology (2017) 0.75
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med (2004) 6.87
Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature (2008) 4.09
Hallucinogens. Pharmacol Ther (2004) 4.01
Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry (2001) 3.26
Early-onset drug use and risk for drug dependence problems. Addict Behav (2008) 3.01
Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron (2007) 2.98
Drug-induced conditioned place preference and aversion in mice. Nat Protoc (2006) 2.77
Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol (2006) 2.60
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med (2002) 2.36
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport (1998) 2.03
Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U S A (1996) 1.94
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci (1984) 1.73
Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis (2005) 1.70
The behavioral pharmacology of hallucinogens. Biochem Pharmacol (2007) 1.35
5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology (2009) 1.24
Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther (2001) 1.20
The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis. Psychopharmacology (Berl) (1995) 1.19
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother (2010) 1.19
Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor. Neuron (1999) 1.18
Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico. J Acquir Immune Defic Syndr (2010) 1.14
Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav (2006) 1.08
Ligand selectivity of D2 dopamine receptors is modulated by changes in local dynamics produced by sodium binding. J Pharmacol Exp Ther (2008) 1.00
Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther (2009) 0.96
Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology (Berl) (2008) 0.95
Neuropsychiatric complications of antiretroviral therapy. Drug Saf (2006) 0.94
Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats. Psychopharmacology (Berl) (2009) 0.93
Future implications: compliance and failure with antiretroviral treatment. J Postgrad Med (2006) 0.88
Effects of DOM and DMT in a proposed animal model of hallucinogenic activity. Prog Neuropsychopharmacol Biol Psychiatry (1985) 0.86
Binding of [3H]dihydrotetrabenazine and [125I]azidoiodoketanserin photoaffinity labeling of the monoamine transporter of platelet 5-HT organelles. Eur J Pharmacol (1990) 0.86
Efavirenz--still first-line king? Expert Opin Drug Metab Toxicol (2008) 0.86
LSD-induced alterations of locomotor patterns and exploration in rats. Psychopharmacology (Berl) (1982) 0.82
Genistein directly inhibits native and recombinant NMDA receptors. Neuropharmacology (2010) 0.82
Efavirenz: enhancing the gold standard. Int J STD AIDS (2003) 0.81
Lysergic acid diethylamide: evidence for stimulation of pituitary dopamine receptors. Psychopharmacology (Berl) (1977) 0.79
Sustiva flashbacks. Posit Aware (2000) 0.77
Characterization of interference with 6 commercial delta9-tetrahydrocannabinol immunoassays by efavirenz (glucuronide) in urine. Clin Chem (2006) 0.77
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A (2002) 4.34
The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci (2009) 3.06
Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab (2012) 2.76
Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol Psychiatry (2006) 2.70
Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci (2008) 2.65
Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell (2011) 2.55
Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science (2006) 2.49
Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal (2007) 2.43
Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun (2009) 2.19
A stomatin-domain protein essential for touch sensation in the mouse. Nature (2006) 2.08
Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) (2007) 1.94
Transdermal protein delivery by a coadministered peptide identified via phage display. Nat Biotechnol (2006) 1.91
Stress-induced relapse to cocaine seeking: roles for the CRF(2) receptor and CRF-binding protein in the ventral tegmental area of the rat. Psychopharmacology (Berl) (2007) 1.86
The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology (Berl) (2007) 1.74
Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia. Nat Chem Biol (2011) 1.70
The anxiogenic drug yohimbine reinstates palatable food seeking in a rat relapse model: a role of CRF1 receptors. Neuropsychopharmacology (2005) 1.68
Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev (2011) 1.66
Selection of reference genes for quantitative gene expression studies in Platycladus orientalis (Cupressaceae) Using real-time PCR. PLoS One (2012) 1.62
In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology (2012) 1.61
Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones. Behav Pharmacol (2013) 1.60
Reversal of pancreatitis-induced pain by an orally available, small molecule interleukin-6 receptor antagonist. Pain (2010) 1.58
CRF system recruitment mediates dark side of compulsive eating. Proc Natl Acad Sci U S A (2009) 1.57
HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci (2012) 1.52
Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. PLoS Biol (2007) 1.48
New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. J Nat Prod (2002) 1.45
Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology (2002) 1.45
Dissociation between opioid and CRF1 antagonist sensitive drinking in Sardinian alcohol-preferring rats. Psychopharmacology (Berl) (2006) 1.37
Synthesis and pharmacological effects of the enantiomers of the N-phenethyl analogues of the ortho and para e- and f-oxide-bridged phenylmorphans. Org Biomol Chem (2008) 1.36
Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT₂A and mGlu₂ receptors in the adult offspring. J Neurosci (2011) 1.36
Deficits in dopamine clearance and locomotion in hypoinsulinemic rats unmask novel modulation of dopamine transporters by amphetamine. J Neurochem (2005) 1.34
Behavioral analyses of GHB: receptor mechanisms. Pharmacol Ther (2008) 1.31
Sigma-1 receptor regulation of voltage-gated calcium channels involves a direct interaction. Invest Ophthalmol Vis Sci (2008) 1.26
Delta-opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats. J Pharmacol Exp Ther (2004) 1.25
Synthesis of rac-(1R,4aR,9aR)-2-methyl-1,3,4,9a-tetrahydro-2H-1,4a-propanobenzofuro[2,3-c]pyridin-6-ol. An unusual double rearrangement leading to the ortho- and para-f oxide-bridged phenylmorphan isomers. Org Biomol Chem (2004) 1.25
Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging. J Pharmacol Exp Ther (2004) 1.24
Corticotropin-releasing factor-1 receptor antagonists decrease heroin self-administration in long- but not short-access rats. Addict Biol (2009) 1.23
Effects of age and caloric intake on glutathione redox state in different brain regions of C57BL/6 and DBA/2 mice. Brain Res (2006) 1.22
Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem (2009) 1.22
Estrogens directly potentiate neuronal L-type Ca2+ channels. Proc Natl Acad Sci U S A (2008) 1.22
Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett (2011) 1.21
Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception. J Pharmacol Exp Ther (2003) 1.21
Kinetic characterization of hypophosphatasia mutations with physiological substrates. J Bone Miner Res (2002) 1.19
Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacology (Berl) (2002) 1.18
Feeding conditions differentially affect the neurochemical and behavioral effects of dopaminergic drugs in male rats. Eur J Pharmacol (2008) 1.18
Patterns of nicotinic receptor antagonism: nicotine discrimination studies. J Pharmacol Exp Ther (2011) 1.18
Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) (2003) 1.17
Constitutive GABAA receptor endocytosis is dynamin-mediated and dependent on a dileucine AP2 adaptin-binding motif within the beta 2 subunit of the receptor. J Biol Chem (2003) 1.16
Coenzyme Q, oxidative stress and aging. Mitochondrion (2007) 1.16
Effect of chronic delivery of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of heroin craving. Biol Psychiatry (2013) 1.16
Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice. J Pharmacol Exp Ther (2002) 1.15
Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats. Psychopharmacology (Berl) (2010) 1.14
Probes for narcotic receptor mediated phenomena. Part 28: new opioid antagonists from enantiomeric analogues of 5-(3-hydroxyphenyl)-N-phenylethylmorphan. Bioorg Med Chem (2002) 1.13
Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett (2005) 1.13
Protracted withdrawal from alcohol and drugs of abuse impairs long-term potentiation of intrinsic excitability in the juxtacapsular bed nucleus of the stria terminalis. J Neurosci (2009) 1.12
Resolving mitochondrial protein complexes using nongradient blue native polyacrylamide gel electrophoresis. Anal Biochem (2009) 1.12
Life span extension in mice by food restriction depends on an energy imbalance. J Nutr (2009) 1.12
Concurrent administration of coenzyme Q10 and alpha-tocopherol improves learning in aged mice. Free Radic Biol Med (2005) 1.10
Effect of coenzyme Q10 intake on endogenous coenzyme Q content, mitochondrial electron transport chain, antioxidative defenses, and life span of mice. Free Radic Biol Med (2005) 1.10
Gonadal hormone modulation of mu, kappa, and delta opioid antinociception in male and female rats. J Pain (2005) 1.10
Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists. Org Biomol Chem (2007) 1.10
Effects of coenzyme Q(10) administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat. Free Radic Biol Med (2002) 1.10
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology (Berl) (2002) 1.10
Combined discriminative stimulus effects of midazolam with other positive GABAA modulators and GABAA receptor agonists in rhesus monkeys. Psychopharmacology (Berl) (2004) 1.10
Abuse liability profile of three substituted tryptamines. J Pharmacol Exp Ther (2011) 1.10
Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Psychopharmacology (Berl) (2004) 1.09
Molecular determinants of picrotoxin inhibition of 5-hydroxytryptamine type 3 receptors. J Pharmacol Exp Ther (2005) 1.09
Effect of long-term caloric restriction on oxygen consumption and body temperature in two different strains of mice. Mech Ageing Dev (2007) 1.09
The selective non-peptidic delta opioid agonist SNC80 does not facilitate intracranial self-stimulation in rats. Eur J Pharmacol (2008) 1.09
Does Helicobacter pylori eradication really reduce the risk of gastric cancer at the population level? Gut (2012) 1.08
Genetic diversity of the critically endangered Thuja sutchuenensis revealed by ISSR markers and the implications for conservation. Int J Mol Sci (2013) 1.08
Converging protein kinase pathways mediate adenylyl cyclase superactivation upon chronic delta-opioid agonist treatment. J Pharmacol Exp Ther (2003) 1.08
Comparison of metabolic rate and oxidative stress between two different strains of mice with varying response to caloric restriction. Exp Gerontol (2008) 1.08
Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice. Br J Pharmacol (2012) 1.07
Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl) (2005) 1.07
High fat diet and food restriction differentially modify the behavioral effects of quinpirole and raclopride in rats. Eur J Pharmacol (2009) 1.07
Eating high-fat chow increases the sensitivity of rats to quinpirole-induced discriminative stimulus effects and yawning. Behav Pharmacol (2010) 1.07
Dopamine D3 receptors mediate the discriminative stimulus effects of quinpirole in free-feeding rats. J Pharmacol Exp Ther (2009) 1.07
Coenzyme Q intake elevates the mitochondrial and tissue levels of Coenzyme Q and alpha-tocopherol in young mice. J Nutr (2003) 1.07
Effects of selective dopaminergic compounds on a delay-discounting task. Behav Pharmacol (2011) 1.06
Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacologic modulation of heroin vs food choice in heroin-dependent rhesus monkeys. Neuropsychopharmacology (2008) 1.06
Nicotine and methamphetamine share discriminative stimulus effects. Drug Alcohol Depend (2007) 1.06
Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception. Psychopharmacology (Berl) (2008) 1.06
Daily treatment with diazepam differentially modifies sensitivity to the effects of gamma-aminobutyric acid(A) modulators on schedule-controlled responding in rhesus monkeys. J Pharmacol Exp Ther (2002) 1.06
Enhanced amplification of GC-rich DNA with two organic reagents. Biotechniques (2009) 1.06
Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction. ACS Chem Neurosci (2012) 1.06
The role of GABAB receptors in the discriminative stimulus effects of gamma-hydroxybutyrate in rats: time course and antagonism studies. J Pharmacol Exp Ther (2003) 1.05
The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats. Neuropsychopharmacology (2004) 1.05
Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology (Berl) (2004) 1.05
You are what you eat: influence of type and amount of food consumed on central dopamine systems and the behavioral effects of direct- and indirect-acting dopamine receptor agonists. Neuropharmacology (2012) 1.04
The sigma-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking. Neuropsychopharmacology (2008) 1.04
Group II metabotropic glutamate receptors and schizophrenia. Cell Mol Life Sci (2009) 1.04
The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. Psychopharmacology (Berl) (2005) 1.04
Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through delta- and micro-opioid receptors independent of antidepressant-like effects. Eur J Neurosci (2006) 1.04